438 Studies Now Enrolling
Phase 1/2, Multicenter, First-In-Human, Dose Escalation and Dose ExpansionStudy of CPO107, a CD47-blocking Bispecific Fusion Protein AdministeredIntravenously to Patients with Advanced CD20-positive Non-HodgkinsLymphoma
Study of CPO107 in Patients with Non-Hodgkin's Lymphoma (NHL)
| Sponsor: | Conjupro Biotherapeutics Inc |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAU1909 |
| U.S. Govt. ID: | NCT04853329 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The main purpose of this research study is to determine if the study drug CPO107 can be used safely in participants who have been diagnosed with non-Hodgkins lymphoma (NHL) and have failed at least two prior conventional anti-cancer drugs. Other purposes of the study are to monitor how the study drug is distributed and broken down inside the body. All patients entering this study will receive CPO107 by intravenous infusion (into the vein).
This study is closed
